OSE Immunotherapeutics Unveils 2026–2028 Strategic Plan With Four Opportunities for Value CreationCompletion of Tedopi’s phase 3 in Non-Small ...

The pharmaceutical supply chain and device development have become intricately linked. Harmonizing formulation development ...

The introduction of MyMineralMix to the United States marks a new stage in the company’s long-term work in personalized micronutrient formulation. After years ...

Cosmo Pharmaceuticals attracted welcome attention from investors and other market watchers after coming out with topline ...

Regarding goods consumption, Wang said China will continue to organize impactful promotion activities so that residents can ...

Post-hoc analysis of RAP-219 Phase 2a data showed early onset of action and consistency of median response over the entire treatment period, ...

BEIJING -- China's top political advisor Wang Huning on Thursday called for the scientific formulation of the 2026 consultation plan based on a thorough understanding of the guiding principles and ...

The Sokoto State Government has approved the 2026–2028 Fiscal Framework, a three-year financial plan that will guide the ...

Watch the next video segment here MIAMI, FL / ACCESS Newswire / December 3, 2025 / iTolerance, Inc. (“iTolerance” or the “Company”), an early-stage privately-held biotechnology company focused on the ...

The FDA has granted orphan drug designation to Birchbiomed’s FS2 as a treatment for idiopathic pulmonary fibrosis, or IPF.

The results showed that Polyrizon’s Trap and Target ™ (T&T) hydrogel exhibited significantly higher mucoadhesion levels compared to the commercial product, supporting potentially prolonged contact at ...

ESTERO, FLORIDA / ACCESS Newswire / December 2, 2025 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) (“Aspire” or the “Company”), a developer of a multi-faceted patent-pending drug delivery technology ...